Lv61
1660 积分 2024-12-14 加入
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study
4天前
已完结
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
26天前
已完结
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
1个月前
已完结
Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity
1个月前
已完结
Regulatory network of BLIMP1, IRF4, and XBP1 triad in plasmacytic differentiation and multiple myeloma pathogenesis
1个月前
已完结
Discovery and Characterization of Novel BLIMP-1 Heterobifunctional Ligand-Directed Degraders
1个月前
已完结
New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms
2个月前
已完结
A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2
2个月前
已完结
Allosteric inhibition of JAK2 with lysine-reactive compounds that bind the pseudokinase domain
2个月前
已完结
Heterozygous human JAK2V617F activates AhR to drive essential thrombocythemia and promote thrombosis
2个月前
已完结
皖公网安备34019202002308
